Cargando…

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers

This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between...

Descripción completa

Detalles Bibliográficos
Autores principales: Taran, Florin-Andrei, Schneeweiss, Andreas, Lux, Michael P., Janni, Wolfgang, Hartkopf, Andreas D., Nabieva, Naiba, Overkamp, Friedrich, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Wöckel, Achim, Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Wallwiener, Diethelm, Brucker, Sara Y., Fasching, Peter A., Fehm, Tanja N., Schütz, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862549/
https://www.ncbi.nlm.nih.gov/pubmed/29576629
http://dx.doi.org/10.1055/s-0044-101613
_version_ 1783308246243606528
author Taran, Florin-Andrei
Schneeweiss, Andreas
Lux, Michael P.
Janni, Wolfgang
Hartkopf, Andreas D.
Nabieva, Naiba
Overkamp, Friedrich
Kolberg, Hans-Christian
Hadji, Peyman
Tesch, Hans
Wöckel, Achim
Ettl, Johannes
Lüftner, Diana
Wallwiener, Markus
Müller, Volkmar
Beckmann, Matthias W.
Belleville, Erik
Wallwiener, Diethelm
Brucker, Sara Y.
Fasching, Peter A.
Fehm, Tanja N.
Schütz, Florian
author_facet Taran, Florin-Andrei
Schneeweiss, Andreas
Lux, Michael P.
Janni, Wolfgang
Hartkopf, Andreas D.
Nabieva, Naiba
Overkamp, Friedrich
Kolberg, Hans-Christian
Hadji, Peyman
Tesch, Hans
Wöckel, Achim
Ettl, Johannes
Lüftner, Diana
Wallwiener, Markus
Müller, Volkmar
Beckmann, Matthias W.
Belleville, Erik
Wallwiener, Diethelm
Brucker, Sara Y.
Fasching, Peter A.
Fehm, Tanja N.
Schütz, Florian
author_sort Taran, Florin-Andrei
collection PubMed
description This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects.
format Online
Article
Text
id pubmed-5862549
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-58625492018-03-23 Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers Taran, Florin-Andrei Schneeweiss, Andreas Lux, Michael P. Janni, Wolfgang Hartkopf, Andreas D. Nabieva, Naiba Overkamp, Friedrich Kolberg, Hans-Christian Hadji, Peyman Tesch, Hans Wöckel, Achim Ettl, Johannes Lüftner, Diana Wallwiener, Markus Müller, Volkmar Beckmann, Matthias W. Belleville, Erik Wallwiener, Diethelm Brucker, Sara Y. Fasching, Peter A. Fehm, Tanja N. Schütz, Florian Geburtshilfe Frauenheilkd This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects. Georg Thieme Verlag KG 2018-03 2018-03-21 /pmc/articles/PMC5862549/ /pubmed/29576629 http://dx.doi.org/10.1055/s-0044-101613 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Taran, Florin-Andrei
Schneeweiss, Andreas
Lux, Michael P.
Janni, Wolfgang
Hartkopf, Andreas D.
Nabieva, Naiba
Overkamp, Friedrich
Kolberg, Hans-Christian
Hadji, Peyman
Tesch, Hans
Wöckel, Achim
Ettl, Johannes
Lüftner, Diana
Wallwiener, Markus
Müller, Volkmar
Beckmann, Matthias W.
Belleville, Erik
Wallwiener, Diethelm
Brucker, Sara Y.
Fasching, Peter A.
Fehm, Tanja N.
Schütz, Florian
Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
title Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
title_full Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
title_fullStr Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
title_full_unstemmed Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
title_short Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
title_sort update breast cancer 2018 (part 1) – primary breast cancer and biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862549/
https://www.ncbi.nlm.nih.gov/pubmed/29576629
http://dx.doi.org/10.1055/s-0044-101613
work_keys_str_mv AT taranflorinandrei updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT schneeweissandreas updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT luxmichaelp updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT janniwolfgang updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT hartkopfandreasd updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT nabievanaiba updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT overkampfriedrich updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT kolberghanschristian updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT hadjipeyman updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT teschhans updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT wockelachim updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT ettljohannes updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT luftnerdiana updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT wallwienermarkus updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT mullervolkmar updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT beckmannmatthiasw updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT bellevilleerik updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT wallwienerdiethelm updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT bruckersaray updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT faschingpetera updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT fehmtanjan updatebreastcancer2018part1primarybreastcancerandbiomarkers
AT schutzflorian updatebreastcancer2018part1primarybreastcancerandbiomarkers